Scientific publications

Recent Articles

Real-World Use of Ubrogepant as Acute Treatment for Migraine with an Anti-Calcitonin Gene-Related Peptide Monoclonal Antibody: Results from COURAGE.
Lipton RB, Contreras-De Lama J, Serrano D, Engstrom E, Ayasse ND, Poh W, Cadiou F, Manack Adams A.
Neurol Ther. 2024 Feb;13(1):69-83. doi: 10.1007/s40120-023-00556-8 Pubmed

Investigating the relationship between sleep and migraine in a global sample: a Bayesian cross-sectional approach.
Stanyer EC, Brookes J, Pang JR, Urani A, Holland PR, Hoffmann J.
J Headache Pain. 2023 Sep 8;24(1):123. doi: 10.1186/s10194-023-01638-6. Pubmed

Real-world effectiveness, satisfaction, and optimization of ubrogepant for the acute treatment of migraine in combination with onabotulinumtoxinA: results from the COURAGE Study.
Manack Adams A, Hutchinson S, Engstrom E, Ayasse ND, Serrano D, Davis L, Sommer K, Contreras-De Lama J, Lipton RB.
J Headache Pain. 2023 Aug 3;24(1):102. doi: 10.1186/s10194-023-01622-0. Pubmed

Intramuscular Electrical Stimulation for the Treatment of Trigger Points in Patients with Chronic Migraine: A Protocol for a Pilot Study Using a Single-Case Experimental Design
Perreault T, Arendt-Nielson L, Fernández-de-Las-Peñas C, Dommerholt J, Herrero P, Hubbard R.
Medicina (Kaunas). 2023 Jul 28;59(8):1380. doi: 10.3390/medicina59081380. Pubmed

Impact of the COVID-19 pandemic on people living with migraine: Results of the MiCOAS qualitative study.
Dawn C. Buse, Maya T. Gerstein, Carrie R. Houts, James S. McGinley, Alyssa A., Uzumcu BA, Kelly P. McCarrier, Alexis Cooke, Nancy M. Touba, Tracy K. Nishida, R. J. Wirth, Richard B. Lipton
Headache. 2022; 62: 284– 293. doi:10.1111/head.14274. Pubmed

Impact of COVID-19 pandemic on migraine management in the United States: insights from migraine tracking app users.
Kato Y, Poh W, Horvath Z, Cadiou F, Shimazu T, Maruki Y.
BMC Neurol. 2021 Sep 9;21(1):345. doi: 10.1186/s12883-021-02378-3. Pubmed.

Can Ketogenic Diet Therapy Improve Migraine Frequency, Severity and Duration?
Haslam RL, Bezzina A, Herbert J, Spratt N, Rollo ME, Collins CE.
Healthcare (Basel). 2021 Aug 26;9(9):1105. doi: 10.3390/healthcare9091105. Pubmed

Multinational descriptive analysis of the real-world burden of headache using the Migraine Buddy application.
Goadsby PJ, Constantin L, Ebel-Bitoun C, Igracki Turudic I, Hitier S, Amand-Bourdon C, Stewart A.
Eur J Neurol. 2021 Jul 26. doi: 10.1111/ene.15037. Pubmed.

Telemedicine Applications for the Evaluation of Patients with Non-Acute Headache: A Narrative Review.
Noutsios CD, Boisvert-Plante V, Perez J, Hudon J, Ingelmo P.
J Pain Res. 2021 Jun 1;14:1533-1542. doi: 10.2147/JPR.S309542. Pubmed.

The impact of Coronavirus disease 2019 (COVID-19) pandemic on migraine disorder.
Haghdoost F, Carcel C, Chandrasekhar D, Rodgers A, Delcourt C.
J Neurol. 2021 May 5:1–7. doi: 10.1007/s00415-021-10590-x. Pubmed.

Systematic evaluation of commercially available pain management apps examining behavior change techniques.
Gamwell KL, Kollin SR, Gibler RC, Bedree H, Bieniak KH, Jagpal A, Tran ST, Hommel KA, Ramsey RR.
Pain. 2021 Mar 1;162(3):856-865. doi: 10.1097/j.pain.0000000000002090. Pubmed.

Recent Presentations and Posters

Real-World Effectiveness of Ubrogepant Among Participants With Prior Treatment Failure: Subgroup Analysis From the UNIVERSE Study
Shewale, Anand R.; Poh, Weijie; Reed, Michael L.; Liu, Jinjie ; Cadiou, Francois ; Burslem, Kate ; Lipton, Richard B.
The American Academy of Neurology annual meeting 2022 (abstract)

Treatment Satisfaction and Optimization With Real-World Use of Ubrogepant for the Acute Treatment of Migraine in Combination With an Anti-Calcitonin Gene–Related Peptide Monoclonal Antibody Preventive: Results From the COURAGE Study
Contreras-De Lama, Janette; Manack Adams, Aubrey Serrano; Daniel Engstrom, Ella; Poh, Weijie; Cadiou, François; Lipton, Richard B.
The American Academy of Neurology annual meeting 2022 (abstract)

Real-World Effectiveness of Ubrogepant for the Acute Treatment of Migraine When Used in Combination With an Anti-Calcitonin Gene–Related Peptide Monoclonal Antibody Preventive: Results From the COURAGE Study
Manack Adams, Aubrey; Contreras-De Lama, Janette ; Serrano, Daniel ; Engstrom, Ella Poh, Weijie ; Cadiou, François; Lipton, Richard B.
The American Academy of Neurology annual meeting 2022 (abstract)

Ubrogepant users' experience - Patients on Ubrogepant, characteristics and outcomes (UNIVERSE STUDY)
A. R. Shewale, W. Poh, M. L. Reed, S. Manthena, F. Cadiou, K. Burslem, R. B. Lipton
The International Headache Congress – IHS and EHF joint congress 2021 (abstract)

Evaluating Real World burden of migraine using Migraine Buddy
P. J. Goadsby, C. Amand, L. Constantin, S. Hitier
The International Headache Congress – IHS and EHF joint congress 2021 (abstract)

Impact of migraine on work productivity and healthcare costs in Malaysia: a retrospective, cross-sectional analysis using self-reported data from the Migraine-Buddy application
K. J. Goh, S. Kalra, P. Nair Ramadasan
The International Headache Congress – IHS and EHF joint congress 2021 (abstract)

Combining UbRogepAnt and Preventives for MiGrainE (COURAGE) Study Using the Migraine Buddy Application: A Novel, Entirely Remote Design for Collecting Real-world Evidence
R. B. Lipton, J. Contreras-De Lama, D. Serrano, E. Engstrom, W. Poh, F. Cadiou, A. Adams
The International Headache Congress – IHS and EHF joint congress 2021 (abstract)